Supplemental Figure 3: A. Swimmers plot showing progressing free survival from the start of second-line therapy comparing patients who received 5-fu based treatment versus targeted therapy. B. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients, excluding those treated with immunotherapy. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. C. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients with an OncoKB level 1 or level 2 alteration. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. D. Swimmers plot showing the progression-free survival in BRAFi-treated patients. Kaplan–Meier overall survival curves comparing patients harboring BRAF class I mutation with a targeted therapy to those who did not. E. Swimmers plots of overall survival comparing treated and untreated targeted therapy cohorts (IDH1/2 mutated, FGFR2i-treated, and ERBB2i-treated patients). F. Kaplan–Meier overall curves comparing overall survival from the start of second-line therapy between treated and untreated samples in the entire immunotherapy cohort, then stratified into MSI patients and TMB-high patient subgroups. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. G. Swimmer’s plot depicting the progression-free survival in patients treated with immunotherapy, with an oncoprint depicting genes commonly altered in MSI tumors and a proportionality plot for the types of mutations within each tumor and sample-level TMB and MSI annotations.